PH12020550878A1 - CLOSED-ENDED DNA VECTORS OBTAINABLE FROM CELL-FREE SYNTHESIS AND PROCESS FOR OBTAINING ceDNA VECTORS - Google Patents

CLOSED-ENDED DNA VECTORS OBTAINABLE FROM CELL-FREE SYNTHESIS AND PROCESS FOR OBTAINING ceDNA VECTORS

Info

Publication number
PH12020550878A1
PH12020550878A1 PH12020550878A PH12020550878A PH12020550878A1 PH 12020550878 A1 PH12020550878 A1 PH 12020550878A1 PH 12020550878 A PH12020550878 A PH 12020550878A PH 12020550878 A PH12020550878 A PH 12020550878A PH 12020550878 A1 PH12020550878 A1 PH 12020550878A1
Authority
PH
Philippines
Prior art keywords
vectors
methods
closed
dna vectors
cell
Prior art date
Application number
PH12020550878A
Other languages
English (en)
Inventor
Ozan Alkan
Robert Michael Kotin
Matthew Stanton
Douglas Anthony Kerr
Carolyn Pelletier
Original Assignee
Generation Bio Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Generation Bio Co filed Critical Generation Bio Co
Publication of PH12020550878A1 publication Critical patent/PH12020550878A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/14011—Baculoviridae
    • C12N2710/14041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/14043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vectore
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/103—Plasmid DNA for invertebrates
    • C12N2800/105—Plasmid DNA for invertebrates for insects
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2820/00—Vectors comprising a special origin of replication system
    • C12N2820/60—Vectors comprising a special origin of replication system from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/48—Vector systems having a special element relevant for transcription regulating transport or export of RNA, e.g. RRE, PRE, WPRE, CTE

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Plant Pathology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PH12020550878A 2018-01-19 2020-06-11 CLOSED-ENDED DNA VECTORS OBTAINABLE FROM CELL-FREE SYNTHESIS AND PROCESS FOR OBTAINING ceDNA VECTORS PH12020550878A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862619392P 2018-01-19 2018-01-19
PCT/US2019/014122 WO2019143885A1 (en) 2018-01-19 2019-01-18 Closed-ended dna vectors obtainable from cell-free synthesis and process for obtaining cedna vectors

Publications (1)

Publication Number Publication Date
PH12020550878A1 true PH12020550878A1 (en) 2021-04-05

Family

ID=67301565

Family Applications (1)

Application Number Title Priority Date Filing Date
PH12020550878A PH12020550878A1 (en) 2018-01-19 2020-06-11 CLOSED-ENDED DNA VECTORS OBTAINABLE FROM CELL-FREE SYNTHESIS AND PROCESS FOR OBTAINING ceDNA VECTORS

Country Status (16)

Country Link
US (1) US12442015B2 (cg-RX-API-DMAC7.html)
EP (1) EP3740571A4 (cg-RX-API-DMAC7.html)
JP (3) JP2021511047A (cg-RX-API-DMAC7.html)
KR (2) KR20250159738A (cg-RX-API-DMAC7.html)
CN (1) CN111868242A (cg-RX-API-DMAC7.html)
AU (1) AU2019210034B2 (cg-RX-API-DMAC7.html)
BR (1) BR112020013319A2 (cg-RX-API-DMAC7.html)
CA (1) CA3088984A1 (cg-RX-API-DMAC7.html)
IL (1) IL275878B2 (cg-RX-API-DMAC7.html)
MA (1) MA51626A (cg-RX-API-DMAC7.html)
MX (1) MX2020005790A (cg-RX-API-DMAC7.html)
MY (1) MY208589A (cg-RX-API-DMAC7.html)
PH (1) PH12020550878A1 (cg-RX-API-DMAC7.html)
SG (1) SG11202005271TA (cg-RX-API-DMAC7.html)
UA (1) UA130154C2 (cg-RX-API-DMAC7.html)
WO (1) WO2019143885A1 (cg-RX-API-DMAC7.html)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2020001593A (es) 2017-08-09 2020-07-13 Bioverativ Therapeutics Inc Moleculas de acido nucleico y usos de las mismas.
AU2019221642A1 (en) * 2018-02-14 2020-07-09 Generation Bio Co. Non-viral DNA vectors and uses thereof for antibody and fusion protein production
JP7602454B2 (ja) 2018-08-09 2024-12-18 バイオベラティブ セラピューティクス インコーポレイテッド 核酸分子及び非ウイルス遺伝子治療のためのそれらの使用
WO2020097417A1 (en) * 2018-11-09 2020-05-14 Generation Bio Co. Modified closed-ended dna (cedna) comprising symmetrical modified inverted terminal repeats
GB201905651D0 (en) 2019-04-24 2019-06-05 Lightbio Ltd Nucleic acid constructs and methods for their manufacture
WO2021011842A1 (en) 2019-07-17 2021-01-21 Generation Bio Co. Synthetic production of single-stranded adeno associated viral dna vectors
DE102020111571A1 (de) 2020-03-11 2021-09-16 Immatics US, Inc. Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren
IL296660A (en) * 2020-03-24 2022-11-01 Generation Bio Co Non-viral DNA vectors and their use for therapeutic expression of factor ix
MX2023001109A (es) 2020-07-27 2023-04-24 Anjarium Biosciences Ag Composiciones de moleculas de adn, metodos para elaborar las mismas, y metodos de usos de las mismas.
US20220243201A1 (en) * 2020-08-23 2022-08-04 Bioverativ Therapeutics Inc. Engineered itr sequences and methods of use
MX2023003019A (es) * 2020-09-16 2023-05-08 Generation Bio Co Vectores de adn de extremo cerrado y usos de estos para expresar fenilalanina hidroxilasa (pah).
GB202014751D0 (en) 2020-09-18 2020-11-04 Lightbio Ltd Targeting vector
GB202014772D0 (en) 2020-09-18 2020-11-04 Lightbio Ltd Nucleic acid construct
CA3209115A1 (en) * 2021-01-25 2022-07-28 Prevail Therapeutics, Inc. Modulation of aav-based gene expression
CN112980862A (zh) * 2021-02-25 2021-06-18 通用生物系统(安徽)有限公司 一种高纯度微环dna的制备方法
JP2024517427A (ja) 2021-04-20 2024-04-22 アンジャリウム バイオサイエンシズ エージー アミロ-α-1,6-グルコシダーゼ、4-α-グルカノトランスフェラーゼをコードするDNA分子の組成物、その作製の方法、及びその使用の方法
US20240216535A1 (en) * 2021-04-27 2024-07-04 Generation Bio Co. Non-viral dna vectors expressing anti-coronavirus antibodies and uses thereof
JP2024515788A (ja) * 2021-04-27 2024-04-10 ジェネレーション バイオ カンパニー 治療抗体を発現する非ウイルスdnaベクター及びその使用
WO2022236016A1 (en) * 2021-05-07 2022-11-10 Generation Bio Co. Lyophilized non-viral dna vector compositions and uses thereof
EP4333886A4 (en) * 2021-05-07 2025-11-12 Generation Bio Co NON-VIRAL DNA VECTORS FOR VACCINE ADMINISTRATION
US20250049961A1 (en) * 2021-12-23 2025-02-13 Generation Bio Co. Scalable and high-purity cell-free synthesis of closed-ended dna vectors
WO2023135273A2 (en) 2022-01-14 2023-07-20 Anjarium Biosciences Ag Compositions of dna molecules encoding factor viii, methods of making thereof, and methods of use thereof
GB202204112D0 (en) 2022-03-23 2022-05-04 Lightbio Ltd Linear construct
EP4293101A1 (en) 2022-06-14 2023-12-20 Asklepios Biopharmaceutical, Inc. Reactor with temperature control and method of using the same
JP2025525583A (ja) 2022-07-19 2025-08-05 ランパート バイオサイエンス インコーポレイテッド 非免疫原性環状非ウイルス性dnaベクター
WO2024040222A1 (en) 2022-08-19 2024-02-22 Generation Bio Co. Cleavable closed-ended dna (cedna) and methods of use thereof
US20260199386A1 (en) * 2022-12-01 2026-07-16 Generation Bio Co. Synthetic single-stranded dna molecules and methods of producing and using the same
WO2024170778A1 (en) 2023-02-17 2024-08-22 Anjarium Biosciences Ag Methods of making dna molecules and compositions and uses thereof
US11993783B1 (en) * 2023-03-27 2024-05-28 Genecraft Inc. Nucleic acid molecule comprising asymmetrically modified ITR for improving expression rate of inserted gene, and use thereof
WO2026085495A1 (en) 2024-10-18 2026-04-23 Generation Bio Co. Synthetic partially single-stranded nucleic acid compositions and uses and methods therefor

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5252479A (en) 1991-11-08 1993-10-12 Research Corporation Technologies, Inc. Safe vector for gene therapy
US6346415B1 (en) * 1997-10-21 2002-02-12 Targeted Genetics Corporation Transcriptionally-activated AAV inverted terminal repeats (ITRS) for use with recombinant AAV vectors
AU2002365514A1 (en) 2001-11-30 2003-06-10 Innogenetics N.V. Therapeutic use of antibodies and fragments thereof binding primate ifn-gamma
EP3176263A1 (en) * 2007-08-10 2017-06-07 Toto Ltd. Method of producing recombinant mammalian cells
US8709778B2 (en) * 2008-10-28 2014-04-29 Xavier Danthinne Method of adenoviral vector synthesis
EP2500434A1 (en) 2011-03-12 2012-09-19 Association Institut de Myologie Capsid-free AAV vectors, compositions, and methods for vector production and gene delivery
EP2970966A4 (en) * 2013-03-15 2016-10-26 Univ North Carolina SYNTHETIC ADENOASSOZED VIRUS INVERTED REPEAT SEQUENCES
IL261524B2 (en) * 2016-03-03 2023-10-01 Univ Massachusetts End-capped linear double-stranded DNA for non-viral gene transfer
WO2019101596A1 (en) 2017-11-21 2019-05-31 Expedeon Ltd Methods and kits for amplification of double stranded dna
AU2019221642A1 (en) 2018-02-14 2020-07-09 Generation Bio Co. Non-viral DNA vectors and uses thereof for antibody and fusion protein production
KR20210119416A (ko) * 2019-01-24 2021-10-05 제너레이션 바이오 컴퍼니 폐쇄-말단 dna (cedna), 및 유전자 또는 핵산 치료 관련 면역 반응을 감소시키는 방법에서의 이의 용도
WO2021011842A1 (en) * 2019-07-17 2021-01-21 Generation Bio Co. Synthetic production of single-stranded adeno associated viral dna vectors
US20220228171A1 (en) * 2019-07-17 2022-07-21 Generation Bio Co. Compositions and production of nicked closed-ended dna vectors

Also Published As

Publication number Publication date
CA3088984A1 (en) 2019-07-25
RU2020127017A (ru) 2022-02-21
AU2019210034A1 (en) 2020-07-09
IL275878B2 (en) 2026-03-01
KR102879598B1 (ko) 2025-11-03
EP3740571A4 (en) 2021-12-08
AU2019210034B2 (en) 2025-03-27
MA51626A (fr) 2020-11-25
SG11202005271TA (en) 2020-07-29
BR112020013319A2 (pt) 2020-12-01
US20210071197A1 (en) 2021-03-11
UA130154C2 (uk) 2025-12-03
IL275878A (en) 2020-08-31
JP2021511047A (ja) 2021-05-06
US12442015B2 (en) 2025-10-14
IL275878B1 (en) 2025-11-01
KR20250159738A (ko) 2025-11-11
JP2025113389A (ja) 2025-08-01
JP2023126487A (ja) 2023-09-07
EP3740571A1 (en) 2020-11-25
KR20200111726A (ko) 2020-09-29
MY208589A (en) 2025-05-19
WO2019143885A1 (en) 2019-07-25
MX2020005790A (es) 2020-10-28
CN111868242A (zh) 2020-10-30

Similar Documents

Publication Publication Date Title
MY208589A (en) Closed-ended dna vectors obtainable from cell-free synthesis and process for obtaining cedna vectors
NZ756132A (en) Method for producing multispecific antibodies
MY171270A (en) Methods of producing isoprene and a co-product
EP2045327B8 (en) Expression enhancing intron sequences
EA200801074A1 (ru) Способы получения искусственных гибридных семян
PH12020550748A1 (en) Synpiii, a promoter for the specific expression of genes in retinal pigment epithelium
WO2021011842A9 (en) Synthetic production of single-stranded adeno associated viral dna vectors
AR070058A1 (es) Enzima bacteriana asociada con la sintesis de ecuol
MX2008011038A (es) Plantas que tienen un rendimiento incrementado y metodo para obtenerlas.
ZA202403308B (en) An efficient new process for synthesis of 2-amino-5-chloro-n-,3-dimethylbenzamide
PH12012502520A1 (en) Plants having enhanced yield-related traits and method for making the same
MY204224A (en) Intermittent electrolysis streams
GB201001524D0 (en) Process for producing coelenteramide or an analog thereof
MY159849A (en) Mammalian expression vector
MX2020003164A (es) Produccion a gran escala de productos liquidos y solidos de trichoderma.
NO20062695L (no) Genvarianter kodende for proteiner fra metabolsk reaksjonsveien til finkjemikalier
MX2021002092A (es) Metodo para producir compuestos de acetato de drimanilo.
WO2021205005A3 (en) Antisense sequences for treating amyotrophic lateral sclerosis
ATE550944T1 (de) Pilzstämme und ein verfahren zur herstellung eines insektizids von diesen stämmen
MX2023002999A (es) Composiciones de cultivo y metodos de su uso para la produccion de vainillina de alto rendimiento.
EP4105230A4 (en) Genetically modified microorganisms that carry out the heterologous production of modified versions of the surfactant protein lv-ranaspumin-1 (lv-rsn-1), the modified versions of said surfactant protein, the synthetic genes encoding said surfactant protein, the expression cassettes containing said synthetic genes, and the expression vectors containing said synthetic genes
SG11201902998SA (en) PROMOTER OF Hspa5 GENE
MX2022006142A (es) Proceso para la sintesis de (3-cloro-2-piridil)hidrazina.
MX380693B (es) Produccion de manool.
MX2020005939A (es) Mejoramiento de la productividad de lipidos de algas a traves de la modificacion genetica de una proteina que contiene un dominio tpr.